Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ARID2 - ALK EML4 - ALK |
| Therapy | Crizotinib |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID2 - ALK EML4 - ALK | lung adenocarcinoma | predicted - sensitive | Crizotinib | Case Reports/Case Series | Actionable | In a clinical case study, Xalkori (crizotinib) treatment resulted in stable disease for 12 months in a lung adenocarcinoma patient harboring two ALK fusions, EML4-ALK (e20:e20) and ARID2-ALK (e12:e23) (PMID: 35144623). | 35144623 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35144623) | Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively. | Full reference... |